Children with end stage renal failure and anaemia have an increased cardiac index and often gross ventricular hypertrophy. The contribution of anaemia to these abnormalities is uncertain. Eleven children with end stage renal failure and anaemia (haemoglobin concentration <90 g/l) were enroiled into a single blind, placebo controlled, crossover study to assess *the cardiovascular effects of reversing anaemia using subcutaneous human recombinant erythropoietin (r-HuEpo). Each limb lasted 24 weeks; seven children completed both limbs of the study.
There are no reports in children with end stage renal failure of cardiovascular changes occurring with r-HuEpo treatment. We have therefore assessed the cardiovascular effects of 24 weeks' r-HuEpo treatment in a group of children with end stage renal failure and anaemia, using a single blind, placebo controlled crossover study design.
Patients and methods Eleven children (nine boys, two girls) were enrolled into the study. Their median age was 6 7 years (range 2 3-12 3) , and median haemoglobin concentration 73 g/l (range 42-81). r-HuEpo for 24 weeks followed by placebo, and five the reverse treatment order. Both the echocardiographer and the family were unaware of the treatment order in each child. Cardiac investigations were performed at baseline and then after 24 and 48 weeks. r-HuEpo (Recormon, Boehringer Mannheim) or placebo were administered subcutaneously twice weekly by the child or parent at home. The volume of all injections was fixed at 0 5 ml. r-HuEpo was commenced at 50 U/kg/week and increased in stepwise increments to a maximum of 400 U/kg/ week by week 12, thereafter adjusted to maintain a target haemoglobin concentration of 105-120 g/l. Each child was assessed by clinical examination, chest radiography, electrocardiography, and echocardiography. Systolic and diastolic blood pressure was measured by auscultation using the largest cuff that could be applied to the upperarm. Thecardiothoracic ratiowasmeasured on each chest radiograph. A standard 12 lead electrocardiogram was performed in the semirecumbent position after five minutes rest (Marquette Instruments). A single experienced observer (JRS) performed all the echocardiograms using the same Hewlett Packard Sonos 1000 machine. Details of the echocardiographic methodology have been described in detail previously.2 A list of the electrocardiographic and echocardiographic measurements is shown in table 2. From these the following were derived. Stoke index (SI)=SV/body surface area Equation 3 .
Cardiac output (CO)= SVx heart rate Equation 4 .
Cardiac index=CO/body surface area Equation 5 .
Minute distance=AoSDxheart rate Equation 6 .
Left ventricular mass index= 0.77{(LVEDD+LVPW+IVS)'-(LVEDD)3} +2-4 Body surface area Equation 7 .
Fractional shortening=(LVEDD-LVESD)/LVEDD Equation 8 .
Total peripheral vascular resistance= mean blood pressure/cardiac output Nine of the 11 children completed a 24 week period of r-HuEpo but only seven children completed both limbs of the study and were included in the analysis; three of the remaining four underwent renal transplantation during the study and one child died; this was related to his primary disease (patient 10). Treatment effects were calculated using statistical methods appropriate for the analysis of crossover trials, after excluding a significant period effect.8 To test for the presence of a treatment effect, the difference in any measured variable between week 24 (end of period 1) and week 48 (end of period 2) is calculated, and the mean difference found in group 1 compared with that found in group 2, using a standard two sample t test. In the absence of a treatment effect the differences are the same, and the t test non-significant.
Results
The relevant results are summarised in table 3. r-HuEpo produced a significant rise in mean haemoglobin from 69 g/l to 115 g/l after 24 weeks' treatment (p=0O0001) (fig 2A) . In association with this there was a significant fall in cardiac index, as a result of a fall in both left ventricular stroke index and heart rate ( fig 2B) . These findings were further supported by a fall in aortic stroke distance and minute distance ( fig  2C) .
Left ventricular end diastolic diameter and shortening fraction fell after r-HuEpo. Although in some patients there was a reduction in thickness of the interventricular septum and left ventricular posterior wall, this did not reach significance after 24 weeks' treatment. The same was true for estimated left ventricular mass index ( fig 2D) . No significant change was found in mitral or tricuspid valve diastolic flow after r-HuEpo. Significant changes in the electrocardiogram after 24 weeks' treatment with r-HuEpo were an increase in the height of the T wave in V5 (p=0 002), and a prolongation of the QT interval (p=005), appropriate in relation to the reduction in heart rate. The mean cardiothoracic ratio fell from 51-6% to 48-9% (nonsignificant). Subjectively there was a reduction in murmur intensity in five of the six children with audible ejection murmurs before r-HuEpo.
Three children on antihypertensive treatment completed an r-HuEpo limb. One required an increase in treatment, one a reduction, and one no change. None We are grateful to the staff of Clinic E and the electrocardiography department, Freeman Hospital for their help with the study, and to Boehringer Mannheim UK for supplying the erythropoietin for the study. Dr K P Morris and Dr J R Skinner are research fellows in child health supported by Newcastle District Research Committee and Child Kidney Fund (KPM) and the National Heart Research Fund (JRS).
